Urinary biomarkers of plant food supplement (PFS) exposure/ intake represent an accurate, non-subjective tool for determining PFS consumption in humans with applications ranging from epidemiology to subject compliance in clinical trials. Ginkgo biloba remains one of the worlds most popular PFS, yet few studies have investigated the uptake and metabolism of its primary unique bioactives: the terpene lactones. To this end, we conducted a dual-dose, acute crossover intervention using Ginkgo biloba supplements in healthy participants (n=12).
Introduction
Ginkgo biloba (ginkgo, also referred to as Maidenhair tree) has a long history of phyto-medicinal use, and is of high commercial significance to the worldwide plant food supplement (PFS) market. It has an association with Chinese herbal medicine dating back 5000 years, with its use as a medical treatment for senility being first recorded over 500 years ago (1) . More recent evidence links ginkgo principals to several promising properties, including anti-platelet activity (2), improved nitric oxide availability (3), wound healing (4), anti-asthmatic activity (5) and neuroprotection (6) . However the evidence from randomized controlled human interventions is less clear, and recent systematic reviews and metaanalyses of Ginkgo efficacy in the areas of cognition in dementia (e.g. Weinmann et al. (7) ; vs. Birks & Evans (8) ) and tinnitus management (e.g. von Boetticher (9) ; vs. Hilton et al. (10) ) are contradictory in their conclusions. Deficiencies in intervention design are a major driver of this controversy. Nevertheless, Ginkgo remains one of the worlds most popular PFS, with combined sales from France, Germany, UK, US, Japan and China worth approximately half a billion dollars (US) in 2011 alone (11) .
The accurate determination of individual PFS intake is vital for related efficacy research. Urinary biomarkers of PFS exposure/ intake can be used to rapidly (and often retrospectively) gauge the intake of large cohorts, assess subject compliance in clinical trials, and quantify the bioavailability of active principals from different PFS preparations. This typically involves collecting urine, either over a 24-hour period or "spot" urine as a single sample, and measuring one or more representative metabolites in the sample using appropriate methodology.
However, the identification of specific biomarkers of intake can be complicated by wide inter-individual variation in the uptake and metabolism of ingested compounds from the PFS of interest, and by the occurrence of the same compounds in other foods, beverages and supplements.
High quality Ginkgo PFS products are commonly based on standardised leaf extracts, such as EGb 761 (Dr. Wilmar Schwabe GmbH & Co.) or LI 1370 (Lichtwer Pharma AG). The German Commission E monograph on Ginkgo requires that such extracts contain less than 5ppm ginkolic acids, a flavonol glycoside content of 22-27% and a terpene lactone content of 5-7%. Capillary LC-ITMS fingerprint analysis of commercial Ginkgo extracts showed that of 72 tentatively identified flavonoids, 42 were glycosides of the flavonols quercetin, isorhamnetin and kampferol (12) . Following hydrolysis to the aglycone forms, these 3 compounds can easily be quantified by HPLC-UV, however, routine use of flavonol aglycone content as a raw material quality indicator may facilitate adulteration (13) . The terpene lactones, including the Ginkgolides (A,B, C and J, see figure 1 ) and Bilobalide (figure 2), can be observed at 220 nm, however response and selectivity is too poor for HPLC analysis (14) . Whilst a wide range of improved analytical techniques for Ginkgo terpenes are now available (for review see (15)), LC-MS has become a well-utilised technique for analysis in biological matrices. Several authors have reported on the pharmacokinetics of terpene lactones in plasma following Ginkgo consumption (16) (17) (18) however to date the majority of studies considering urinary derivatives have focused on the flavonols (19) and their common downstream metabolites (20) .
Quercetin, isorhamnetin and kampferol are not unique to Ginkgo biloba, being widely found in foods such as onions, red wine, tomatoes and tea. As such, the specificity of these flavonols would be insufficient to quantitatively determine ginkgo intake within participants consuming an open diet. Therefore, we investigated the utility of terpene lactones as urinary biomarkers of ginkgo intake via an acute randomized, 2-dose crossover intervention study.
Experimental Procedures

Reagents and Reference Materials
All solvents (methanol, ethanol, ethyl acetate) were of HPLC grade or higher, obtained from VWR. LC-MS grade water was produced using a combination Elix/MilliQ purification system (Millipore, UK). Sodium azide (>99%) and EDTA (>98.5%) were obtained from Sigma (UK). Reagent grade ascorbic acid was obtained from Extrasynthese (France)
All reference standards were of HPLC grade (>95%). Taxifolin was obtained from 
Study Design
The intervention was a dual dose, crossover study, in which participants were randomly allocated to consume either 1 or 2 x 500 mg tablets at a single sitting (in line with manufacturers dosage instructions). Each intervention stage required participants keep to a polyphenol-free diet for 48 hrs, avoiding tea, coffee, alcohol, fruit and vegetable derived foods, chocolate, and high bran cereal derived foods such as brown bread, whole grain breakfast cereals and brown rice. At the end of the first 24 hrs, a urine sample was collected as a compliance measure. The intervention dose was then consumed, and urine was collected as a 24hr pool. After completion of the 24 hr pool, participants were free to cross over to the next intervention stage.
Urine was collected in clean, dry, 3 L polypropylene vessels (Urisafe, obtained from VWR, UK), each containing a 3 g aliquot of ascorbic acid powder to act as a preservative. Filled vessels were kept cool and dark, and collected the day after use. The weight and volume of urine was noted, and following homogenisation, 3 x 10 ml aliquots were placed in 15 ml centrifuge tubes (BD Biosciences, UK). A 100 l aliquot of sodium azide solution (10% w/v) was added to each tube as an anti-bacterial agent. The tubes were vortexed (10 sec) then stored at -20°C until extraction.
Analysis of Ginkgo Supplements
Supplements were from Boots UK Ltd., branded "Ginkgo Biloba Brain Health" tablets. Each disk shaped compressed 500 mg tablet was stated to contain 120 mg of ginkgo biloba extract, standardised to provide 28. The gradient was held at 8% solvent B for 5 min, then increased linearly to 40% over 15 min, up to 90% in 2 min, was held for a further 2 min, then decreased to 8% over 2 min and was re-equilibrated over 8 min. The first 3 min of each run was diverted to waste. The MS ran with an interface temperature set to 350°C, using nebuliser and drying gas flow rates of 1.5-and 15L/min, respectively. The analysis was performed in negative SIM mode, optimized using reference standards. Bilobalide and taxifolin internal standard were followed on m/z 325.1 and 303.1 respectively. In addition to m/z equivalent to [M-1] -, the ginkgolides also formed persistent formate adducts, i.e. [M + 45] -, which were also followed. 
Analysis of Participant Urine
Urine samples were defrosted at room temperature immediately before extraction, placed in an ultrasonic water bath (5 min) then vortexed (30 sec) to ensure homogeneity. Each urine sample was extracted in triplicate. Each 200 L aliquot of urine was combined with 20 L of an aqueous solution of ascorbic acid (1% w/v) and EDTA (0.1% w/v), 100 L of ethanol containing 2 g/ml ethyl gallate (IS1) and 1 ml of ethyl acetate in a 1.5 ml centrifuge tube. The solution was vortexed, placed in an ultrasonic water bath and vortexed again to extract soluble material. The tubes were centrifuged at 17,000 R.C.F. (10 min) and the upper layer removed. A second 1 ml aliquot of ethyl acetate was added to the pellet, and the extraction procedure repeated. All extracts were dried under nitrogen at room temperature and frozen at -20°C. On the day of analysis, the second extracts were reconstituted with 70 l of ethanol, vortexed, placed in an ultrasonic water bath and vortexed again. A 50 l aliquot of the reconstituted second extract was combined with the corresponding first (dried) extract, which was similarly vortexed and sonicated. A 50 l aliquot of ascorbic acid solution (0.2% w/v) containing taxfolin (IS2) at 8 g/ml was added to the combined first and second extract, which was then vortexed and centrifuged. The supernatant was placed in an amber 300 l HPLC vial, which was capped and kept at 8°C until analysis.
A modified sample preparation method was developed to prepare polar material for pilot analyses, wherein ethyl acetate was substituted for methanol. Methanol was removed from the samples using an EZ2+ centrifugal evaporator (Genevac, UK) using the HPLC drying program for 1 hr. Water was subsequently removed from the samples via freeze drying at -50°C for 24 hrs. Reconstitution occurred as described above.
Analysis was conducted on an Agilent LC-MS-MS system comprising a 1200 SL binary pump, well plate autosampler set to 8°C, and column oven set to 35°C, connected to a 6410a triple quadrupole mass spectrometer. Each 5 l sample was separated via the same chromatographic method detailed above. The first 3 min of each run was diverted to waste, and thereafter directed into the MS interface set to 350°C, using nebuliser pressure of 30 psi and drying gas flow 
Results
Supplement Analysis
On average, each tablet weighed 517.0 ± 5.5 mg. Tablets in batch 1 delivered 7.9 ± 0.1 mg of target ginkolides and bilobalide, whilst batch 2 tablets delivered 8.0 ± 0.2 mg, equivalent to 20.3 ± 0.3 and 20.7 ± 0.4 mol. This marginally exceeded the 7.2 mg of terpene lactones per tablet stated by the manufacture. As can be seen in figure 3 , on a molar basis bilobalide was the single largest contributor to the terpene lactone profile at 7.8 ± 0.2 mol per capsule, with ginkgolides A B and C making roughly equal contributions. Ginkgolide J was a comparatively minor contributor to the overall terpene lactone profile.
Urinary biomarker analysis
Separation of target analytes in urine can be seen in figure 4 . Elevated levels of terpene lactones compared to baseline indicated 100% compliance in all participants, regardless of randomization order. However, it is possible that the minimum 24 hr wash out was slightly too short to ensure complete clearance of all target compounds in all participants, as very low levels of terpene lactones could be observed in the baseline urine of 7 volunteers at the start of the second dose. In the majority of cases this was judged not to influence the outcome of the study: total terpene lactone concentrations at baseline ranged just 0.01-0.3% that of the post-supplement concentrations. However in 3 individuals, baseline terpene lactone concentrations equated 2-6% that of the corresponding postsupplement urine. As such, statistical analysis was performed both including and excluding these 3 individuals.
For the full n=12 group, average total terpene lactones excreted were 7.5±2.6
mol following low dose ginkgo, and 17.1 ±3.6 mol following high dose supplementation (see figure 5) In line with a dose-dependent excretion of compounds, the percentage of the initial dose recovered in urine was similar between low and high dosing, with total terpene lactone recoveries of 37±13 % and 42±9%, respectively. However, there was a marked difference between the recoveries of each individual compound (see figure 6 ). At high dose, 34±14% and 36±10% of bilobalide and ginkgolide B were recovered intact in urine, respectively. However, only 8±4 % and 4±2 % of the high dose were recovered for ginkgolides J and C. The calculated recovery of ginkgolide A was 109±26%, ranging from 57% to 149%.
Pilot phase 2 conjugate identification
Following successful identification of intact ginkgolides in urine, a further exploratory investigation was performed to seek classical phase 2 metabolites, namely sulfates, glucuronides and methylated forms. However, MRM experiments, based on anticipated post-collision compound fragmentation, did not identify any potential conjugates produced at a level approaching that of the intact ginkgolides, with no signals observed in non-polar solvent-extracted urine.
However, in urine prepared via a polar inclusive method, a small transition return was observed corresponding to a possible methylated bilobalide (339>163, retention time 20.4 min) with approx 30% relative peak area of bilobalide itself. Whilst methylation would increase non-polarity and thus retention on a C18 bonded phase, the retention of this analyte is almost double that of proposed parent (10.9 min). The identity of this relatively minor compound therefore requires further clarification.
Discussion
The uptake and metabolism of flavonols from plant foods is well established. For example, quercetin is typically the most abundant flavonol in commercial gingko extracts (13), but exists as a variety of glycosides of which rutin (querecetin-3-Orhamnoglucoside) is a major form. Rutin is not significantly absorbed in the small intestine, requiring cleavage via colonic glycosidases before uptake in the large intestine (21) . Upon absorption, quercetin can be metabolised both within the epithelial cells and in the liver to form methlyated, glucuronidated and sulphated metabolites, which are the forms present in circulating plasma and urine (22) . Typically, the proportion of the dose appearing in urine is quite low. was not performed for pure ginkgolide A. Therefore, we propose that the identity of methylated ginkgolide C is in question.
In conclusion, following the consumption of ginkgo biloba supplements at doses relevant to typical consumer use, it is apparent that bilobalide, and ginkgolides A and B are i) excreted in urine at sufficient levels to be routinely detectable via LC-triple quadrupole analysis and ii) are excreted in a dose-dependent manner.
Therefore, these compounds are recommended as biomarkers of Ginkgo biloba consumption. 
